Chris Boshoff, Pfizer Oncology chief development officer, said lessons from the rapid pace of the company’s COVID-19 vaccine program are being applied to elranatamab and other cancer therapies.

Private Company Edition: New capital for health care and life science innovations include a fund for royalty deals, additional anti-infective funding, early-stage money and public health-focused cash. Also, Day One reveals a $130m series B venture round and Notch closes an $85m series A round.

Multiple COVID-19 vaccines, including from RDIF and Novavax, could get accelerated approvals in India in the first half of calendar 2021, expanding the range at the country’s disposal. J&J's vaccine is expected to follow although it still hasn’t begun local trials, while Pfizer has temporarily withdrawn an application.

A strong year is predicted for biopharma business with investment and deal making set to continue apace. Executives across industry share their forecasts for the year ahead.